Despite intense investigation, the roles of the various hormones that influence the prostate gland in the aetiology of prostatic cancer remain to be elucidated. Some evidence has emerged from the work of the British Prostate Study Group to suggest that hormone analysis will allow the identification of these patients presenting with prostatic cancer who are at greater risk of rapid disease progression and more effective and aggressive treatment should probably be considered for these patients. The monitoring of hormone changes in the plasma of patients being treated is also seen to be an advantage in determining the course of therapy and a recent assessment of the use of the new LH-RH analogue (ICI 118630) for prostatic cancer therapy appears very encouraging. The value of specific antisera to proteins, isolated for various types of prostatic tissue, in drug-targetting studies, is being assessed in a number of centres and may again offer a new approach to treatment. Navacelles, 3410 Montpellier, France.
Oestrogens and antioestrogens regulate the production of specific proteins by, and the growth of, breast cancer cells. The mechanisms involved have been studied in culture using oestrogen receptor (RE) positive cell lines derived from metastatic breast cancers. In MCF7 cells oestradiol increases progesterone receptor levels and the production of a 52,000 dalton (52K) glycoprotein which is released into the culture medium. Oestrogens also transform the cell ultrastructure: the number and length of microvillae and the production of secretory granules are increased, while attachment of cells to plastic is decreased. Antioestrogens, Tamoxifen and Progestins, do not themselves induce the 52K protein, but inhibit its induction by oestrogens. Using specific antibodies, the presence of this protein has been demonstrated in several pleural metastases of breast cancer and in primary breast cancer, but not in the normal mammary cell line HBL100 or in adenofibroma. Since it is secreted or shed into the culture medium, the 52K protein is a potential circulating marker of oestrogen dependency in breast cancer. Oestrogen increases the growth of RE positive cells in vitro if the culture medium is sufficiently depleted of endogenous oestrogens and other mitogens. This direct effect of oestrogens in cell culture does not exclude the existence of additional indirect effects in vivo, mediated by growth factors produced by other tissues (oestromedins). However, it does allow the mechanism by which oestrogens stimulate the proliferation of RE positive cell lines to be studied in vitro. Several indirect lines of evidence suggested that oestrogens might stimulate the growth of breast cancer cells by inducing them to produce growth factors which would then stimulate their proliferation (Autocrine mechanism). We have found that non dialysable, protease sensitive, oestrogen induced factors from conditioned media *Enquiries to the BACR Secretariat, c/o Institute of Biology, 20 Queensberry Place, London SW7 2DZ. promote the growth of E2 deprived MCF7 cells and of RE negative cells. These factors are retained on Con A sepharose. The recent preparation of monoclonal antibodies to the 52K protein or other oestrogen regulated glycoproteins released by MCF7 cells are responsible for this mitogenic activity. Antioestrogens appear to decrease the production of these factors in the medium; their action being mediated either by the oestrogen receptor (Tamoxifen) or by the progesterone receptor (Progestins).
We conclude that oestrogen responsive human mammary cell lines provide simple model systems which can faithfully reproduce the in vivo effect of oestrogens and antioestrogens in patients. They are therefore useful for understanding the mechanisms of hormone regulation of breast cancer and for improving its medical management. We have investigated their use in (a) detecting micrometastases and (b) radio-localisation. In terms of the former application we are currently substituting a monoclonal antibody against milk fat globule membrane (LICR-LON-M8) for a polyclonal antiserum and it appears to have an equal ability to detect micrometastases in bone marrow.
Currently using the polyclonal antiserum, we can detect micrometastases in 28% of patients with primary breast cancer. Using the same monoclonal we have labelled it with '1tlndium-diethylenetriaminepentaaceticacid complex and this has been shown to localise in bone metastases in nearly all patients with overt skeletal disease both by autoradiography and external scanning.
A final application that we have investigated is the use of antibodies in killing breast cancer cells in bone marrow. If we could achieve this we could rescue patients with "cleaned-up" bone marrow after high-dose therapy. We have evaluated one such monoclonal (LICR-LON-Fib75) which is cytotoxic for breast cancer cells with rabbit complement. Since its effects in the colony-formingcapacity of the bone marrow are variable we are also exploring the use of toxin-linked LICR-LONFib75.
None of these monoclonals are breast cancerspecific and a major component of the work of this group is in trying to raise a breast-specific monoclonal reagent. The phenomenon of "programmed" cell death or apoptosis (shrinkage necrosis) has been suggested as an important factor in explaining the observed slow growth rates of tumours as compared to rates calculated on content of cycling cells (Wyllie et al., 1980, Int. Rev. Cytol., 68, 251 The production of anti-tumour monoclonal antibodies has prompted the development of conjugates with anti-tumour agents for specific targeting to tumour sites. Monoclonal antibody 791T/36 (mouse IgG2b), against the human osteogenic sarcoma cell line 791T, was radiolabelled with 125I, and localized in xenografts of 791T in immunodeprived mice. Kinetic studies showed that the maximum degree of localization was achieved 3 to 4 days after antibody administration. The maximum tumour level of antibody achieved was 80ygg-' of tissue following injection of 100-200mg kgI body weight of 791T/36 antibody.
The vinca alkaloid Vindesine (VDS) was conjugated covalently to 791T/36 antibody (3:1 to 6:1 molar ratios). These conjugates were cytotoxic in vitro specifically for target cells expressing the 791T/36 defined antigen and 1251 labelled conjugates localized in vivo in 791T xenografts. The therapeutic effects of conjugate was tested against 791T xenografts. Mice were injected at 3 to 4 day intervals with up to 180mgkg-' 791T/36-5mg kg-' VDS/injection (total doses up to 1.6gkg-' 791T/36-45mgkg-' VDS) and this significantly retarded tumour growth with no toxicity to the mice. Free antibody had no influence on tumour growth. Free VDS was significantly tumour suppressive at doses equivalent to those in the conjugate, but was also markedly toxic to the mice since the doses used exceeded the established acute LD50 of the drug (6.3mgkg-1, Todd et al., 1976 J. Toxicol. Environ. Health, 1, 843).
These studies suggest that drug-antibody conjugates could have considerable potential for selective anti-tumour therapy. In evaluating monoclonal antibody-drug conjugates as anti-tumour agents, one potential problem is the emergence of resistant tumour cell clones. In addition to selection for drug-resistance it is possible that clones of diminished antigenicity could arise as a result of modulation or selection. We have measured both parameters in "resistant" clones of a human osteogenic sarcoma line (791T) isolated after treatment with a monoclonal antibody-methotrexate (MoAb-MTX) conjugate.
Parental cells exposed at low density in vitro to MoAb-MTX containing the equivalent of 50 or lOOngml-' methotrexate (MTX) showed plating efficiencies of 0.28% and 0.08% of control levels, respectively. Of 15 colonies isolated at these doses and subsequently propagated, 11 failed to undergo more than a few cell divisions and only 4 developed into cloned lines. The "resistant" clones were assayed for antigenicity by flow cytometry using fluorescein isothiocyanate-conjugated monoclonal antibody, and for drug-resistance by assessing their plating efficiency in free MTX. Two clones showed antibody binding within the normal range for the parental 791T line, and two were more antigenic. Three of the clones were as susceptible to MTX toxicity as 791T cells (IC50 8 to l0ngml-') and the fourth was only slightly less sensitive (IC,0 17 ng ml -'). These findings suggested that the clones would not resist a further exposure to the MoAb-MTX conjugate, and this was confirmed by showing that the IC50 of conjugate for both parental cells and clones was in the range 1.5 to 3 ng ml-I (in terms of MTX).
It is concluded that cells emerging after exposure to a cytotoxic conjugate are not necessarily resistant, but may either be incapable of unlimited growth or sensitive to further attack by the same conjugate. The aim of this study was to measure the in vitro sensitivities to chemotherapeutic drugs of continuous cell lines derived from human tumours of one histological type. Eight lines derived from transitional cell cancers of the human bladder, MGH-U1, MGH-U2, T24, RT112, TCCSUP, 253J, HT1376 and RT4, were exposed to a cell cycle phase-specific drug, methotrexate and a cell cycle specific drug, adriamycin. The in vitro sensitivities following exposure for 24 h to a range of drug concentrations were measured using a clonogenic assay on plastic. We have shown that three of these lines, MGH-Ul, MGH-U2 and T24 are crosscontaminated (O'Toole et al., 1983, Nature, 301, 429) . The in vitro sensitivities of these three lines were similar, but the remaining five lines showed a wide range of response. The proportion of clonogenic cells surviving exposure to lOOngml-1 methotrexate ranged from 1.5% for MGH-Ul to 89.5% for HT1376, and to 30ngml-1 adriamycin from 0.7% for MGH-Ul to 42% for HT1376. The sensitivities of the cell lines showed the same rank order for each drug. Cytotoxicity was also related to growth rate, in that the higher the population doubling time and colony forming efficiency the more sensitive were the cells to each drug. In Many drugs are required in solution at short notice for an in vitro chemosensitivity assay. They are often made up in phosphate buffered saline (PBS) or saline and stored frozen until required. However, (a) it has been suggested that solutions of BCNU are unstable under these conditions, (b) some drugs have very short half lives in solution, and (c) I have found that aqueous solutions of 2,5-diaziridinyl-3,6-bis(2-hydroxyethyl-amino)-1,4-benzoquinone (BZQ) irreversably precipitate on being frozen. These instances suggest that care ought to be taken in the preparation and storage of drug solutions for in vitro use. Some drugs are very stable in solution (prednisolone, cytosine arabinoside) so that they can be stored at 4°C for some months with no detrimental effects; solutions of others need to be stored frozen, but 1-2h at room temperature will not affect them significantly (vincristine, vinblastine, vindesine Benznidazole has been reported to enhance the response of mouse tumours to CCNU at plasma and tumour concentrations which should be readily attainable in man (Twentyman & Workman, (1983) Br. J. Cancer, 48, 17) . This enhancement is considered greater than that seen in normal tissues, resulting in a net therapeutic gain. As part of a phase I assessment of this combination we have determined the plasma, urine and tumour pharmacokinetics of benznidazole by reverse phase HPLC. Twenty-six patients have received benznidazole in combination with CCNU, the benznidazole dose being increased in successive groups of patients from 4mg kg-' to 30mg kg-1. Both drugs were given orally, benznidazole preceding CCNU by 3 h. No evidence of saturation kinetics has been seen at doses currently used. The mean plasma half life (ti) was 12.8+0.5h (s.e., n=25). Plasma peak concentration and AUC were linearly related to dose over the whole range. As an example the average peak plasma concentration at 8 mg kgwas 13.6 + 1 mg kl-1 (n = 7). The median peak time was 4 h. Approx. 60% of the drug was protein bound. Approx. 6% of the dose was excreted unchanged in the urine, the rest being unaccounted for. Benznidazole concentrations have been measured, at varying times, after oral administration of the drug, in biopsies from 11 patienrs with brain tumours and 6 patients with tumours in other sites. A plateau of maximum concentration is seen over 2-6 h with mean tumour plasma ratios of 88% for gliomas and 72% for non-brain tumours. Absolute tumour concentrations of 8-9 mg ml -I were readily achieved with doses of 8mg kg-1. We have shown that it is possible to achieve in man plasma and tumour levels of benznidazole which, in the mouse model, produce effective enhancement of CCNU response.
Comparison of in vitro chemosensitivities
An assessment of staging procedures in patients with small cell carcinoma of the bronchus (SCCB) Validity of items cannot be established directly since no standards exist. Estimates of validity were made indirectly by comparisons with other methods, by comparisons between items using factor analysis and by comparisons with physician scores in a total of 177 breast cancer patients.
Patients scores were generally highly correlated to physician assessments with coefficients >0.6 in 25/31 items although the variance of patients scores was greater than that of physicians. Scores were highly correlated to scores in equivalent categories of the Sickness Impact Profile with 6/7 coefficients > 0.6 for items which were directly comparable. The factorial composition of the items' scores revealed 5 closely inter-correlated groups of items compatible with clinical experience. Quality of life is highly relevant to management of the Ca patient. However, difficulties in its assessment are well known. This Department has attempted an improved method by means of a selfreport questionnaire. A sample of Ca patients (nlOO) and of control subjects (n80) were asked to describe "the kind of person I am" by selecting items from a "pool" of bi-polar items, e.g. "happysad" etc. Subjects were then required to describe perception of their ideal self, i.e. "the kind of person I should like to be". Factor analysis provided a statistical method for data reduction into clusters of homogeneous items or factors. A two-factor solution was adopted, viz. a factor of "intrapsychic functioning" and a factor of "anticipation of the future". Taking the first factor only, as an example it is apparent that at its pole of "unsatisfactory functioning", items such as "often depressed", "seldom relaxed" etc. were the items chosen. Conversely, the "satisfactory functioning" pole was characterised by their polar alternatives, i.e. "seldom depressed" etc. Computation of factorscores facilitated group values which indicate position on a linear scale, having a zero mean with unit s.d.'s + on either side. Results indicate statistically significant discrepancies between Ca patients and control Ss (subdivided into non-Ca patients (n30) and non-patient Ss (n50)) in "intrapsychic functioning" scores (analysis of variance = P < 0.05). Differences between these discreet groups (using students' t) were as follows: Ca patients and non-Ca patients P= <0.01; Ca patients and non-patient Ss P= <0.01. Statistically significant differences also differentiated Ca patients from control Ss in the size of discrepancy between actual and ideal self-perceptions (invariably greater in the case of Ca patients). We hypothesise that refinement of the measurement of such selfperceptions by means of a self-evaluation questionnaire will greatly enhance assessment of quality of life. Etoposide is a semi-synthetic podophyllotoxin derivative active in a variety of malignancies. It is frequently administered orally but bioavailability via this route is variable. The effect of dose on the absorption of etoposide is unknown and has therefore been studied in six patients with lung carcinoma, acting as their own controls. All were ambulant with normal hepatic and renal function. Patients were fasted for 12h prior to treatment with doses of 200, 400, and 600mg using oral capsules on 3 consecutive days. Very often, in autologous bone marrow transplantation, the marrow cannot be returned to the patient for some time after aspiration. This is generally because the drug(s) given to the patient have a finite clearance time and the marrow cannot be reinfused until the drug(s) have reached a non toxic level. During this time the marrow could be cryopreserved but this results in loss of stem cells, is costly and time consuming. The alternative is to refrigerate the marrow until it can be returned but clearly there is a limit to how long it will remain viable. In both human and mouse marrow it is possible to measure progenitor cells committed to the granulocyte/macrophage pathway (GM-CFC) but this in itself is no sure test of marrow viability. We performed parallel studies between refrigerated human marrow and mouse marrow in their capacity to produce GM-CFC with time at 4°C. In addition we used the mouse marrow to repopulate lethally irradiated mice. The mouse marrow inoculum was chosen to be just sufficient to keep the mice alive at the beginning of the experiment so that any decline in repopulating ability was reflected in terms of reduced animal survival. The GM-CFC numbers of both mouse (Abelson, 1978 , Cancer Treat. Rep., 62, 1999 . To test this hypothesis the concentrations of plasma biopterins, CSF biopterins, homovanillic acid and 5 hydroxindolacetic acid were estimated in 77 children with ALL at various stages of treatment. Crithidia bioassay was used for total biopterin measurement and HPLC for HVA and 5 HIAA. There was a significant elevation of plasma biopterins (P<0.001) associated with chemotherapy which persisted during maintenance treatment. This was not, however, accompanied by a corresponding decrease in HVA and 5HIAA. Moreover the trend in treated cases was towards higher levels than anticipated when corrected for the patient's age. This has been described in the experimental animal and it seems likely that MTX independent pathways are utilized to maintain CSF neurotransmitter levels (Nichol, 1983, Proc. Natl Acad. Sci., 80, 1546). There was no evidence in patients studied sequentially that cranial irradiation altered CSF biopterins, HVA or 5HIAA. It seems unlikely therefore that the prophylactic administration of neurotransmitters such as L-dopa, carbidopa or 5HT would protect against neurotoxicity, as has been previously suggested (Cotton, 1978, Lancet, ii, 484 IFNRx) and heart failure (pt without overt heart disease but had received adriamycin in the past) were noted in 3 different pts on S2. Pharmacokinetic studies in pts on S2 showed a sharp rise in serum IFN with a peak at 1 hr (1-4.5 KUml -1) followed by a rapid decline (mean 1/2 life -2.5 h). Levels of peripheral blood lymphocyte's surface HLA antigen were studied in 7 pts on Days 0, 1, 3 and 5, using monoclonal anti HLA-ABC and fl2 microglobulin antibodies. 2/3 pts on S2 showed a marked rise in reactivity by Day 5 (1:800 to 1:6400). 1/4 pts on S1 showed a marginal increase and 3 none. In conclusion, IFN The object of the experiment was to see whether colitis increases the susceptibility of the rat to the colonic carcinogen dimethyl hydrazine (DMH) . Colitis was induced in adult, male Sprague Dawley rats by intrarectal injection of 10% acetic acid (IRAA) through 3cm of PE240 polythene tubing under ether anaesthesia. In preliminary experiments we showed that a consistent degree of histological inflammation was produced up to 12 cm from the anus. Three groups of 14 rats were studied: group A received IRAA then 20 weekly s.c. injections of 10mg DMHkg-l in EDTA base; group B received IRAA then 20 weekly s.c. injections of EDTA base alone; group C received IR saline then 20 DMH injections. Eight rats from group A were killed because of severe colitis; all colons were dilated and most had perforated. One rat in group B died with a jejunal tumour at 17 weeks. The remaining rats were sacrificed at 20 weeks. No metastatic lesions were found in any rat and group B rats had no colonic tumours. Adenocarcinomas were present in the colons of all group A rats and 11/13 group C rats; group A rats had significantly more tumours per colon (Wilcoxon test, P<0.01); there were a total of 25 tumours in the 6 group A rats and 19 in the 13 group C rats. The stage of the tumours was the same in both groups and most had penetrated the submucosa, one tumour in each group penetrated through the bowel wall. The tumours in group A were significantly more distal (Wilcoxon test, P<0.01) with most tumours occurring within 10cm from the anus whereas in group C tumours were more common in the proximal and mid colon. We conclude that DMH injections increase the severity of colitis induced by acetic acid and that the presence of colitis alters both the number and distribution of DMH induced colon cancers in the rat. The case for bile acids as promoters of colorectal carcinogenesis rests on human epidemiological data and animal experiments. If direct exposure of colorectal mucosa to bile acids altered the composition of the faecal flora, itself implicated as a modulator of carcinogenesis, animal experiments might have limited relevance to human carcinogenesis. The promotional effect of sodium deoxycholate (SDC) was tested in male SpragueDawley rats (n=70) which had received a 6-week course of azoxymethane (total dose 90 mg kg-1 s.c.). For the next 18 weeks 2 groups received thrice weekly intrarectal instillations of 1 ml 0.12 M SDC (n = 25) or 1 ml N saline (n = 25). Controls had no instillations (n = 20). At sacrifice (28 weeks), colorectal tumour yield (controls 2.4 + 0.4 per rat: mean + s.e.) was unaffected by intrarectal saline (2.8 + 0.5) but was almost trebled by intrarectal SDC (6.4+0.5) P<0.01. SDC also increased mean colonic crypt depth by 9% compared with the other 2 groups (P<0.001). Other rats (n=9) received intrarectal SDC or saline or no instillations without carcinogen and were killed at 12 weeks. Total colonic bacterial counts showed no consistent differences between groups. Sodium deoxycholate strongly promotes experimental colorectal carcinogenesis. This effect is probably due to its tropic action on the mucosa and is not related to any concurrent change in bacterial flora. The polycyclic aromatic hydrocarbon chrysene is a weakly active carcinogen on mouse skin, but the dihydrodiol precursor of its "bay-region" diolepoxide is more carcinogenic than the parent compound. Ether extracts of hamster embryo cell cultures and mouse skin in vivo treated with chrysene were examined for the presence of dihydrodiol metabolites by t. 1 .c. and h.p.l.c. In addition the chrysene-nucleoside adducts formed in cultured hamster embryo cells, a rat liver microsomal metabolizing system containing DNA and mouse skin in vivo treated with 3H-labelled chrysene were examined by Sephadex LH20 column chromatography and by h.p.l.c. on Zorbax ODS.
All three possible dihydrodiols of chrysene were detected in hamster embryo cells and mouse skin treated with chrysene. A chrysene triol was also found in mouse skin extracts. In hamster embryo cells, the major DNA-adducts had chromatographic properties identical to those of adducts formed when the anti isomer of the "bay-region" diolepoxide of chrysene reacts with DNA. Both guanosine-and adenosine-hydrocarbon adducts were detected. NMR studies on the guanosine adducts showed that the hydrocarbon is attached at the exocyclic amino group of guanine. In the ratliver microsomal preparations and in mouse skin treated with 3H-chrysene, adducts having chromatographic properties identical to those formed when anti-chrysene-1,2-diol 3,4-oxide reacts with DNA were also detected. Additional adducts were also present, however, which differed in their chromatographic mobilities from synthetic DNAchrysene adducts formed from anti-chrysene-1,2-diol 3,4-oxide. The results show that metabolic activation of chrysene occurs via this "bay-region" diol-epoxide but suggest that, in some biological systems, this is not the sole route for the metabolic activation of chrysene. combined with non cryopreserved autologous marrow transplantation. Forty-five of the children were given a "priming" dose of cyclophosphamide (300 mg m -2) one week before treatment with melphalan. All children developed profound neutropenia and thrombocytopenia following high dose melphalan; the nadir of the neutrophil and platelet counts occurring at median intervals of 7 and 10 days respectively. The duration of neutropenia (median 11 days) and the duration of thrombocytopenia (median 18 days) did not appear to be affected by the dose of melphalan, suggesting that the initial recovery of the peripheral blood count results from the engrafted autologous marrow. There was a highly significant negative correlation between the nucleated cell count of the reinfused marrow and the period of neutropenia (P<0.001) and a significant negative correlation The Natural Killer (NK) activity of peripheral blood lymphocytes (PBL) and whole blood from patients with malignant lymphoma, prior to treatment, was found to be significantly depressed when compared with controls. This is consistent with an intrinsic defect in the cell-mediated immune system, which is commonly found in these patients. A positive correlation was observed between the level of natural killing of PBL from HD patients and the age of the patients, although this was not seen with non-HD patients or with controls. However, among non-HD patients a positive correlation was observed between NK activity and the stage of disease, i.e., stage III and IV patients had significantly higher levels of NK activity than stage I and II patients. There was no correlation between the level of NK activity of lymphoma patients and either the histological type of disease or the sex of patients. NK activity of PBL from the majority of patients tested (12/18) could be boosted by pre-incubation with interferon and similarly the activity of whole blood samples from 7/10 patients was boosted by interferon. Using the monoclonal antibody Leu-7 as an NK marker, it was shown that the number of cells expressing this antigen in the peripheral blood of non-Hodgkin's patients was within the normal range, although expression of did not correlate with NK activity. Preliminary studies suggest that the number of Leu-7+ cells in HD patients is also in the normal range. The functional status of natural killer (NK) cell activity was assessed in patients undergoing surgery for digestive tract carcinoma or benign conditions. The level of natural killing was assessed in peripheral venous blood, the aortic blood supply to the tumour, and the tumour draining venous blood. NK cell activity of peripheral venous blood taken from cancer patients was significantly depressed compared with benign controls (pre-operative blood samples). In addition, assessment of the activity present in the blood draining the primary tumour site was shown to be significantly less than the activity present in the aortic blood suggesting that lymphocyte function is influenced as a result of passage through the tumour site. Plasma samples from either the tumour venous blood supply, or the peripheral venous supply were assessed for their effect on natural killing, mediated by peripheral blood lymphocytes from normal individuals. Blood plasma recovered from tumour draining blood caused significant (P=0.01) inhibition of NK cell killing of K562 targets in the majority of tests performed, whereas the corresponding peripheral venous blood from the same patients was only inhibitory in 25 per cent of cases. There was no significant change in the total number of blood lymphocytes before and after passage through the tumour (aortic versus tumour-venous blood lymphocytes) or in total white blood cell counts. Fluorescent staining with monoclonal antibody against lymphocyte surface markers also failed to reveal significant alterations in the level of Tlymphocytes and We have previously presented quantitative data regarding the migration of unfractionated human peripheral blood lymphocytes into threedimensional collagen matrices (Schor et al., J. Cell Biol., (1983 ), 96, 1089 . Using this experimental system, we now present data regarding the comparative migratory behaviour of fractionated T and B lymphocyte subsets. Enriched populations of T and B lymphocytes were prepared by standard rosetting techniques using sheep red blood cells. The cellular constituents of the enriched populations were estimated by immunofluorescent microscopy using BAI (Hybritech) and UCHTI (supplied by Dr P. Beverley) monoclonal antibodies; the enriched lymphocyte populations contained 90% T cells and 70% B cells respectively. When plated on the surface of the collagen gel matrix, T and B cells were observed to enter the collagen matrix at the same rate. Once within the collagen matrix, however, T cells migrated significantly faster than B cells. As previously shown for the unfractionated lymphocytes, the migration of both T and B cells was found to occur by a random walk mechanism.
